7210 Wareham Drive, Tampa, FL 33647
November 2, 2023 WW reported results for its 3rd quarter. Management reported that: “We have successfully returned WeightWatchers to subscriber growth, with Q3 end of period subscribers up 6% year-over-year to 4.0 million. This is a significant achievement and a direct result of our work in reinvigorating our core product,” said Sima Sistani, the company’s […]
Weight Watchers Reports 3rd Quarter Results Read More »
Sept. 13, 2023 On August 8, Lilly reported that its second-quarter income jumped 85% from the same period a year ago, driven in large part by Mounjaro, which generated $979.7 million in sales for the quarter, compared to $16 million in the year-ago period and $569 million in the first quarter of this year. In
Obesity Drug Sales Continue To Soar Read More »
August 20, 2023 Boehringer Ingelheim could soon stake a claim in the lucrative obesity treatment market after the pharma company said it has advanced a candidate into three Phase III trials following promising data. Servodutide, the company’s glucagon/glucagon-like peptide 1 (GLP-1) receptor dual agonist co-developed with Zeland Pharma, demonstrated up to 19% weight loss after
More Obesity Drugs in the Pipeline – Boehringer Ingelheim Read More »
Aug. 8, 2023 Second quarter 2023 revenue decreased 34.7% to $296.2 million from $453.3 million for the second quarter of 2022, primarily driven by a decrease in the number of active earning OPTAVIA Coaches and the decline in the productivity per active earning OPTAVIA Coach. The average revenue per active earning OPTAVIA Coach was $5,578, compared to $6,667 for the second quarter last year, a
Medifast Reports Q2 Results Read More »
Aug. 5, 2023 WW reported its second quarter results yesterday. End of Period Subscribers of 4.1 million Revenues of $226.8 million Operating Income of $26.3 million; excluding the net impact of restructuring charges and acquisition transaction costs, adjusted operating income of $33.9 million Full Year Fiscal 2023 Guidance: Revenues are expected to be in the
Weight Watchers Reports 2nd Quarter 2023 Results Read More »
June 5, 2023 There is no doubt that the new obesity drugs (Wegovy, Ozempic) are hot and in high demand, but there is a disturbing new trend developing. Since the brand name drugs often cost $1,000 to $1,300 per month and are not covered by insurance, people are looking for cheaper alternatives. That’s where compounding
Semaglutide Gold Rush Is On, Compounding Pharmacies Read More »
March 20, 2023 Marketdata LLC, Tampa, FL, has just released it 17th Edition of its best-selling market research report: “The U.S. Weight Loss & Diet Control Market”. At 427 pages, with 160 Tables & Charts and 34 in-depth diet company competitor profiles, this is the most comprehensive analysis anywhere of the market. Some findings… The
Weight Loss Market Recovers to $75 Billion – New Marketdata Report Read More »